KRW 11640.0
(-5.6%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 330.29 Billion KRW | 9.63% |
2022 | 301.29 Billion KRW | 16.27% |
2021 | 259.13 Billion KRW | 9.26% |
2020 | 237.18 Billion KRW | 2.44% |
2019 | 231.54 Billion KRW | 6.23% |
2018 | 217.96 Billion KRW | -7.54% |
2017 | 235.73 Billion KRW | -1.74% |
2016 | 239.9 Billion KRW | 17.73% |
2015 | 203.77 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 333.92 Billion KRW | 1.1% |
2024 Q2 | 304.51 Billion KRW | -8.81% |
2023 Q1 | 313.77 Billion KRW | 4.14% |
2023 FY | 330.29 Billion KRW | 9.63% |
2023 Q4 | 330.29 Billion KRW | -3.06% |
2023 Q3 | 340.73 Billion KRW | 6.16% |
2023 Q2 | 320.96 Billion KRW | 2.29% |
2022 FY | 301.29 Billion KRW | 16.27% |
2022 Q2 | 271.05 Billion KRW | 2.35% |
2022 Q1 | 264.84 Billion KRW | 2.2% |
2022 Q4 | 301.29 Billion KRW | 7.22% |
2022 Q3 | 281.01 Billion KRW | 3.67% |
2021 FY | 259.13 Billion KRW | 9.26% |
2021 Q2 | 257.73 Billion KRW | -0.41% |
2021 Q1 | 258.79 Billion KRW | 9.11% |
2021 Q3 | 258.71 Billion KRW | 0.38% |
2021 Q4 | 259.13 Billion KRW | 0.17% |
2020 FY | 237.18 Billion KRW | 2.44% |
2020 Q1 | 237.59 Billion KRW | 2.62% |
2020 Q4 | 237.18 Billion KRW | -2.63% |
2020 Q3 | 243.58 Billion KRW | -0.19% |
2020 Q2 | 244.04 Billion KRW | 2.71% |
2019 Q1 | 230.25 Billion KRW | 5.64% |
2019 Q4 | 231.54 Billion KRW | 7.56% |
2019 FY | 231.54 Billion KRW | 6.23% |
2019 Q3 | 215.26 Billion KRW | -6.47% |
2019 Q2 | 230.15 Billion KRW | -0.04% |
2018 FY | 217.96 Billion KRW | -7.54% |
2018 Q4 | 217.96 Billion KRW | -5.73% |
2018 Q3 | 231.22 Billion KRW | -1.1% |
2018 Q2 | 233.79 Billion KRW | 0.71% |
2018 Q1 | 232.13 Billion KRW | -1.53% |
2017 Q3 | 243.09 Billion KRW | 7.33% |
2017 Q4 | 235.73 Billion KRW | -3.03% |
2017 FY | 235.73 Billion KRW | -1.74% |
2017 Q2 | 226.5 Billion KRW | 0.0% |
2016 FY | 239.9 Billion KRW | 17.73% |
2015 FY | 203.77 Billion KRW | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Yuyu Pharma, Inc. | 77.85 Billion KRW | -324.227% |
Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 64.477% |
Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 53.289% |
HANDOK Inc. | 449.7 Billion KRW | 26.553% |
Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -285.541% |
Yuhan Corporation | 712.33 Billion KRW | 53.632% |
Dong-A ST Co., Ltd. | 631.91 Billion KRW | 47.731% |
SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -1978.042% |
Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 61.225% |
Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -517.042% |
Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -60.434% |
Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -339.391% |
MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -123.482% |
Hana Pharm Co., Ltd. | 70.4 Billion KRW | -369.159% |
Yuyu Pharma, Inc. | 77.85 Billion KRW | -324.227% |
Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -806.499% |
REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -31.512% |
Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -49.654% |
JW Holdings Corporation | 827.51 Billion KRW | 60.086% |
Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 24.417% |
Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 43.712% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | 12.989% |
Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -316.504% |
Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -372.067% |
Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -36.006% |
Yuyu Pharma, Inc. | 77.85 Billion KRW | -324.227% |
Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 32.596% |
Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 61.506% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | 12.989% |
Yuhan Corporation | 712.33 Billion KRW | 53.632% |
Jeil Pharma Holdings Inc | 477.81 Billion KRW | 30.873% |
Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -141.146% |
Suheung Co., Ltd. | 516.66 Billion KRW | 36.072% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | 12.989% |
Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -113.732% |
Korea United Pharm Inc. | 89.96 Billion KRW | -267.135% |
CKD Bio Corp. | 170.76 Billion KRW | -93.425% |
Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -35.514% |
Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -109.502% |
Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -667.784% |
Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -316.504% |
Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 47.781% |
Boryung Corporation | 373.1 Billion KRW | 11.475% |
Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -58.645% |
Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -60.434% |
JW Lifescience Corporation | 96.44 Billion KRW | -242.475% |